시장보고서
상품코드
1338919

다리에병 시장 점유율, 규모, 동향, 산업 분석 보고서 : 치료법, 용도, 최종사용자, 지역별, 부문별 예측(2023-2032년)

Darier Disease Market Share, Size, Trends, Industry Analysis Report, By Treatment (Medication, Surgery, and Others); By Application; By End- User; By Region; Segment Forecast, 2023-2032

발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 112 Pages | 배송안내 : 1-2일 (영업일 기준)


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최신 조사에 따르면, 세계 다리에병 시장 규모는 2032년까지 7,412만 달러에 달할 것으로 예상됩니다. 이 조사 보고서는 현재 시장 역학에 대한 자세한 인사이트와 향후 시장 성장에 대한 분석을 제공합니다.

다리에병은 새로운 의료 트렌드의 출현과 함께 확산될 것으로 예상됩니다. 이 질환의 부작용을 해결하기 위해 더 많은 피부과 치료법이 등장하고, 연구자들은 새로운 치료법을 개발하기 위해 많은 재정적 지원을 받게 될 것으로 보입니다. 다리에병(모낭각화증)은 ATP2A2 유전자의 돌연변이로 인해 발생하는 희귀한 유전성 피부질환입니다. 이 질환은 일반적으로 두피, 이마, 가슴, 등 및 기타 신체 부위에 나타나는 사마귀 모양의 구진이나 반점이 특징입니다.

다리에병은 희귀한 질환이기 때문에 시장이 매우 작습니다. 그러나 캐슬 크릭 제약과 호스 테라퓨틱스를 포함한 특정 기업들은 희귀 피부질환 치료제 개발에 주력하고 있습니다. 레티노이드와 칼시뉴린 억제제 등 다래끼병 치료에 사용되는 약물 중 일부는 다른 피부 질환 치료에도 사용된다는 사실은 이러한 약물의 시장을 확대하는 데 도움이 될 수 있습니다.

그러나 환자 수가 적고 희귀질환 치료제 개발 비용이 높기 때문에 이 분야에 투자하는 기업의 수는 제한적일 수 있습니다. COVID-19 사태는 의료업계에 큰 영향을 미치고 있으며, 많은 의료진과 시설이 COVID-19 환자 치료에 전념하고 있습니다. 이로 인해 다발성 경화증과 같은 희귀 질환을 포함한 다른 질환의 진단과 치료가 지연되고 있습니다. 또한, COVID-19는 임상시험과 의약품 개발 프로그램을 중단시켜 다리에병에 대한 새로운 치료법 확보에 영향을 미칠 수 있습니다. 안전에 대한 우려와 의료 시설에 대한 환자의 접근 제한으로 인해 많은 임상시험이 지연되거나 중단되고 있습니다.

다리에병 시장 보고서 하이라이트

예측 기간 동안 외과 수술이 업계 시장 분야를 지배할 것으로 예상됩니다. 통증과 불편함을 줄이면서 결과를 개선할 수 있는 외과 수술의 능력은 산업 확장의 주요 요인입니다.

외용 레티노이드는 향후 1년간 시장에서 높은 점유율을 차지할 것으로 예상됩니다. 증상 치료에 있어 이러한 약물의 효과로 인해 향후 몇 년 동안 시장 성장의 원동력이 될 것으로 예상됩니다.

피부과 의사는 2022년에 가장 큰 점유율을 차지했습니다. 그들은 처방을 담당하고, 환자 지원을 제공하고, 이 질병의 치료에 중요한 역할을 하기 때문에 시장에 영향을 미치는 주요 세력입니다.

북미 지역의 수요는 예측 기간 동안 상당한 성장을 보일 것으로 예상됩니다. 시장의 주요 촉진요인은 의료 서비스 선택의 확대와 의료비 상승 등 여러 요인으로 인해 향후 몇 년 동안 상승할 것으로 예상됩니다.

목차

제1장 서론

제2장 주요 요약

제3장 조사 방법

제4장 세계의 다리에병 시장에 관한 인사이트

  • 다리에병 시장 - 최종사용자 현황
  • 다리에병 시장 역학
    • 성장 촉진요인과 기회
      • 재생에너지원 수요 증가
      • 전력 소비 수요 증가
    • 성장 억제요인과 과제
      • 높은 초기 비용
  • PESTEL 분석
  • 다리에병 시장 최종사용자 동향
  • 밸류체인 분석
  • COVID-19 감염증의 영향 분석

제5장 세계의 다리에병 시장, 치료별

  • 주요 조사 결과
  • 서론
  • 의학
  • 수술
  • 기타

제6장 세계의 다리에병 시장, 용도별

  • 주요 조사 결과
  • 서론
  • 국소 레티노이드
  • 경구 레티노이드
  • 기타

제7장 세계의 다리에병 시장, 최종사용자별

  • 주요 조사 결과
  • 서론
  • 피부과의
  • 홈케어
  • 병원
  • 전문 클리닉

제8장 세계의 다리에병 시장, 지역별

  • 주요 조사 결과
  • 서론
    • 다리에병 시장 평가, 지역별, 2019-2032년
  • 다리에병 시장 - 북미
    • 북미 : 다리에병 시장, 치료별, 2019-2032년
    • 북미 : 다리에병 시장, 최종사용자별, 2019-2032년
    • 북미 : 다리에병 시장, 용도별, 2019-2032년
    • 다리에병 시장 - 미국
    • 다리에병 시장 - 캐나다
  • 다리에병 시장 - 유럽
    • 유럽 : 다리에병 시장, 치료별, 2019-2032년
    • 유럽 : 다리에병 시장, 최종사용자별, 2019-2032년
    • 유럽 : 다리에병 시장, 용도별, 2019-2032년
    • 다리에병 시장 - 영국
    • 다리에병 시장 - 프랑스
    • 다리에병 시장 - 독일
    • 다리에병 시장 - 이탈리아
    • 다리에병 시장 - 스페인
    • 다리에병 시장 - 네델란드
    • 다리에병 시장 - 러시아
  • 다리에병 시장 - 아시아태평양
    • 아시아태평양 : 다리에병 시장, 치료별, 2019-2032년
    • 아시아태평양 : 다리에병 시장, 최종사용자별, 2019-2032년
    • 아시아태평양 : 다리에병 시장, 용도별, 2019-2032년
    • 다리에병 시장 - 중국
    • 다리에병 시장 - 인도
    • 다리에병 시장 - 말레이시아
    • 다리에병 시장 - 일본
    • 다리에병 시장 - 인도네시아
    • 다리에병 시장 - 한국
  • 다리에병 시장 - 중동 및 아프리카
    • 중동 및 아프리카 : 다리에병 시장, 치료별, 2019-2032년
    • 중동 및 아프리카 : 다리에병 시장, 최종사용자별, 2019-2032년
    • 중동 및 아프리카 : 다리에병 시장, 용도별, 2019-2032년
    • 다리에병 시장 - 사우디아라비아
    • 다리에병 시장 - 아랍에미리트
    • 다리에병 시장 - 이스라엘
    • 다리에병 시장 - 남아프리카공화국
  • 다리에병 시장 - 라틴아메리카
    • 라틴아메리카 : 다리에병 시장, 치료별, 2019-2032년
    • 라틴아메리카 : 다리에병 시장, 최종사용자별, 2019-2032년
    • 라틴아메리카 : 다리에병 시장, 용도별, 2019-2032년
    • 다리에병 시장 - 멕시코
    • 다리에병 시장 - 브라질
    • 다리에병 시장 - 아르헨티나

제9장 경쟁 상황

  • 확장과 인수 분석
    • 확대
    • 인수
  • 제휴/협업/합의/공개

제10장 기업 개요

  • AbbVie
  • Amneal Pharmaceuticals
  • Bausch Health Companies
  • BridgeBio Pharma
  • Galderma
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • Johnson and Johnson
  • Laminar Pharma
  • Mayne Pharma
  • Merck
  • Novartis
  • Pfizer
  • Sawai Pharmaceutical
  • Sigmapharm Laboratories
  • Sun Pharmaceutical
  • Teva Pharmaceutical
  • Tolmar Pharmaceuticals
  • Validus Pharmaceuticals
  • Viatris
KSM 23.09.27

The global darier disease market size is expected to reach USD 74.12 million by 2032, according to a new study by Polaris Market Research. The report "Darier Disease Market Share, Size, Trends, Industry Analysis Report, By Treatment (Medication, Surgery, and Others); By Application; By End- Use; By Region; Segment Forecast, 2023-2032" gives a detailed insight into the current market dynamics and provides analysis on future market growth.

Darier disease is anticipated to spread as new healthcare trends emerge. More dermatological treatments will be available to address the condition's side effects, and researchers will receive sizeable financial support to create novel remedies. Darier disease, or keratosis follicularis, is a rare genetic skin disorder caused by mutations in the ATP2A2 gene. The disease is characterized by wart-like papules and plaques that typically appear on the scalp, forehead, chest, back, and other body areas.

Due to the condition's rarity, the market for Darier disease is quite small. Yet, certain businesses, including Castle Creek Pharmaceuticals & Hoth Therapeutics, are focused on creating treatments for uncommon skin conditions. The fact that some of the medications used to treat Darier disease, including retinoids and calcineurin inhibitors, are also used to treat other skin disorders may help to increase the market for these medications.

However, the small patient population and the high cost of developing rare disease therapies may limit the number of companies investing in this area. The COVID-19 pandemic has significantly impacted the healthcare industry, with many healthcare providers and facilities focused on treating patients with COVID-19. This has led to delays in diagnosing and treating other medical conditions, including rare diseases like Darier disease. Additionally, the pandemic has disrupted clinical trials and drug development programs, which may impact the availability of new treatments for Darier disease. Many trials have been delayed or suspended due to safety concerns and restrictions on patient access to healthcare facilities.

Darier Disease Market Report Highlights

Surgery is expected to dominate the industry's market sector during forecast period. The ability of the surgical industry to reduce pain and discomfort while improving results is the major factor driving its expansion.

Topical Retinoid will account for a higher share of the market in the upcoming year. Due to the effectiveness of these medications in treating the condition's symptoms, the primary driver driving the market is predicted to grow over the next several years.

Dermatologist accounted for the largest share in 2022. They are the primary force influencing the market because they are in charge of prescribing, offering patient support, and playing a crucial part in the care of this ailment.

The demand in North America is expected to witness significant growth during forecast period. The primary driver of the market is anticipated to rise in the upcoming years as a result of a number of factors, including the expansion of healthcare service options and rising healthcare costs.

Polaris Market Research has segmented the Darier Disease Market report based on treatment, application, end- user and region:

Darier Disease, Treatment Outlook (Revenue - USD Million, 2019 - 2032)

  • Medical
  • Surgery
  • Others

Darier Disease, Application Outlook (Revenue - USD Million, 2019 - 2032)

  • Topical Retinoids
  • Oral Retinoids
  • Others

Darier Disease, End- User Outlook (Revenue - USD Million, 2019 - 2032)

  • Dermatologist
  • Homecare
  • Hospitals
  • Specialty Clinics

Darier Disease, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Darier Disease Market Insights

  • 4.1. Darier Disease Market - End- User Snapshot
  • 4.2. Darier Disease Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increase in demand for renewable sources of energy
      • 4.2.1.2. Rise in demand for electricity consumption
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High initial costs
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Darier Disease Market End- User Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Darier Disease Market, by Treatment

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Darier Disease Market, by Treatment, 2019-2032 (USD Million)
  • 5.3. Medical
    • 5.3.1. Global Darier Disease Market, by Medical, by Region, 2019-2032 (USD Million)
  • 5.4. Surgery
    • 5.4.1. Global Darier Disease Market, by Surgery, by Region, 2019-2032 (USD Million)
  • 5.5. Others
    • 5.5.1. Global Darier Disease Market, by Others, by Region, 2019-2032 (USD Million)

6. Global Darier Disease Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Darier Disease Market, by Application, 2019-2032 (USD Million)
  • 6.3. Topical Retinoids
    • 6.3.1. Global Darier Disease Market, by Topical Retinoids, by Region, 2019-2032 (USD Million)
  • 6.4. Oral Retinoids
    • 6.4.1. Global Darier Disease Market, by Oral Retinoids, by Region, 2019-2032 (USD Million)
  • 6.5. Others
    • 6.5.1. Global Darier Disease Market, by Others, by Region, 2019-2032 (USD Million)

7. Global Darier Disease Market, by End- User

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Darier Disease Market, by End- User, 2019-2032 (USD Million)
  • 7.3. Dermatologist
    • 7.3.1. Global Darier Disease Market, by Dermatologist, By Region, 2019-2032 (USD Million)
  • 7.4. Homecare
    • 7.4.1. Global Darier Disease Market, by Homecare, By Region, 2019-2032 (USD Million)
  • 7.5. Hospitals
    • 7.5.1. Global Darier Disease Market, by Hospitals, By Region, 2019-2032 (USD Million)
  • 7.6. Specialty Clinics
    • 7.6.1. Global Darier Disease Market, by Specialty Clinics, By Region, 2019-2032 (USD Million)

8. Global Darier Disease Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Darier Disease Market Assessment, By Geography, 2019-2032 (USD Million)
  • 8.3. Darier Disease Market - North America
    • 8.3.1. North America: Darier Disease Market, by Treatment, 2019-2032 (USD Million)
    • 8.3.2. North America: Darier Disease Market, by End- User, 2019-2032 (USD Million)
    • 8.3.3. North America: Darier Disease Market, by Application, 2019-2032 (USD Million)
    • 8.3.4. Darier Disease Market - U.S.
      • 8.3.4.1. U.S.: Darier Disease Market, by Treatment, 2019-2032 (USD Million)
      • 8.3.4.2. U.S.: Darier Disease Market, by End- User, 2019-2032 (USD Million)
      • 8.3.4.3. U.S.: Darier Disease Market, by Application, 2019-2032 (USD Million)
    • 8.3.5. Darier Disease Market - Canada
      • 8.3.5.1. Canada: Darier Disease Market, by Treatment, 2019-2032 (USD Million)
      • 8.3.5.2. Canada.: Darier Disease Market, by End- User, 2019-2032 (USD Million)
      • 8.3.5.3. Canada: Darier Disease Market, by Application, 2019-2032 (USD Million)
  • 8.4. Darier Disease Market - Europe
    • 8.4.1. Europe: Darier Disease Market, by Treatment, 2019-2032 (USD Million)
    • 8.4.2. Europe.: Darier Disease Market, by End- User, 2019-2032 (USD Million)
    • 8.4.3. Europe: Darier Disease Market, by Application, 2019-2032 (USD Million)
    • 8.4.4. Darier Disease Market - UK
      • 8.4.4.1. UK: Darier Disease Market, by Treatment, 2019-2032 (USD Million)
      • 8.4.4.2. UK.: Darier Disease Market, by End- User, 2019-2032 (USD Million)
      • 8.4.4.3. UK: Darier Disease Market, by Application, 2019-2032 (USD Million)
    • 8.4.5. Darier Disease Market - France
      • 8.4.5.1. France: Darier Disease Market, by Treatment, 2019-2032 (USD Million)
      • 8.4.5.2. France.: Darier Disease Market, by End- User, 2019-2032 (USD Million)
      • 8.4.5.3. France: Darier Disease Market, by Application, 2019-2032 (USD Million)
    • 8.4.6. Darier Disease Market - Germany
      • 8.4.6.1. Germany: Darier Disease Market, by Treatment, 2019-2032 (USD Million)
      • 8.4.6.2. Germany.: Darier Disease Market, by End- User, 2019-2032 (USD Million)
      • 8.4.6.3. Germany: Darier Disease Market, by Application, 2019-2032 (USD Million)
    • 8.4.7. Darier Disease Market - Italy
      • 8.4.7.1. Italy: Darier Disease Market, by Treatment, 2019-2032 (USD Million)
      • 8.4.7.2. Italy.: Darier Disease Market, by End- User, 2019-2032 (USD Million)
      • 8.4.7.3. Italy: Darier Disease Market, by Application, 2019-2032 (USD Million)
    • 8.4.8. Darier Disease Market - Spain
      • 8.4.8.1. Spain: Darier Disease Market, by Treatment, 2019-2032 (USD Million)
      • 8.4.8.2. Spain.: Darier Disease Market, by End- User, 2019-2032 (USD Million)
      • 8.4.8.3. Spain: Darier Disease Market, by Application, 2019-2032 (USD Million)
    • 8.4.9. Darier Disease Market - Netherlands
      • 8.4.9.1. Netherlands: Darier Disease Market, by Treatment, 2019-2032 (USD Million)
      • 8.4.9.2. Netherlands.: Darier Disease Market, by End- User, 2019-2032 (USD Million)
      • 8.4.9.3. Netherlands: Darier Disease Market, by Application, 2019-2032 (USD Million)
    • 8.4.10. Darier Disease Market - Russia
      • 8.4.10.1. Russia: Darier Disease Market, by Treatment, 2019-2032 (USD Million)
      • 8.4.10.2. Russia.: Darier Disease Market, by End- User, 2019-2032 (USD Million)
      • 8.4.10.3. Russia: Darier Disease Market, by Application, 2019-2032 (USD Million)
  • 8.5. Darier Disease Market - Asia Pacific
    • 8.5.1. Asia Pacific: Darier Disease Market, by Treatment, 2019-2032 (USD Million)
    • 8.5.2. Asia Pacific.: Darier Disease Market, by End- User, 2019-2032 (USD Million)
    • 8.5.3. Asia Pacific: Darier Disease Market, by Application, 2019-2032 (USD Million)
    • 8.5.4. Darier Disease Market - China
      • 8.5.4.1. China: Darier Disease Market, by Treatment, 2019-2032 (USD Million)
      • 8.5.4.2. China.: Darier Disease Market, by End- User, 2019-2032 (USD Million)
      • 8.5.4.3. China: Darier Disease Market, by Application, 2019-2032 (USD Million)
    • 8.5.5. Darier Disease Market - India
      • 8.5.5.1. India: Darier Disease Market, by Treatment, 2019-2032 (USD Million)
      • 8.5.5.2. India.: Darier Disease Market, by End- User, 2019-2032 (USD Million)
      • 8.5.5.3. India: Darier Disease Market, by Application, 2019-2032 (USD Million)
    • 8.5.6. Darier Disease Market - Malaysia
      • 8.5.6.1. Malaysia: Darier Disease Market, by Treatment, 2019-2032 (USD Million)
      • 8.5.6.2. Malaysia.: Darier Disease Market, by End- User, 2019-2032 (USD Million)
      • 8.5.6.3. Malaysia: Darier Disease Market, by Application, 2019-2032 (USD Million)
    • 8.5.7. Darier Disease Market - Japan
      • 8.5.7.1. Japan: Darier Disease Market, by Treatment, 2019-2032 (USD Million)
      • 8.5.7.2. Japan.: Darier Disease Market, by End- User, 2019-2032 (USD Million)
      • 8.5.7.3. Japan: Darier Disease Market, by Application, 2019-2032 (USD Million)
    • 8.5.8. Darier Disease Market - Indonesia
      • 8.5.8.1. Indonesia: Darier Disease Market, by Treatment, 2019-2032 (USD Million)
      • 8.5.8.2. Indonesia.: Darier Disease Market, by End- User, 2019-2032 (USD Million)
      • 8.5.8.3. Indonesia: Darier Disease Market, by Application, 2019-2032 (USD Million)
    • 8.5.9. Darier Disease Market - South Korea
      • 8.5.9.1. South Korea: Darier Disease Market, by Treatment, 2019-2032 (USD Million)
      • 8.5.9.2. South Korea.: Darier Disease Market, by End- User, 2019-2032 (USD Million)
      • 8.5.9.3. South Korea: Darier Disease Market, by Application, 2019-2032 (USD Million)
  • 8.6. Darier Disease Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Darier Disease Market, by Treatment, 2019-2032 (USD Million)
    • 8.6.2. Middle East & Africa.: Darier Disease Market, by End- User, 2019-2032 (USD Million)
    • 8.6.3. Middle East & Africa: Darier Disease Market, by Application, 2019-2032 (USD Million)
    • 8.6.4. Darier Disease Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Darier Disease Market, by Treatment, 2019-2032 (USD Million)
      • 8.6.4.2. Saudi Arabia.: Darier Disease Market, by End- User, 2019-2032 (USD Million)
      • 8.6.4.3. Saudi Arabia: Darier Disease Market, by Application, 2019-2032 (USD Million)
    • 8.6.5. Darier Disease Market - UAE
      • 8.6.5.1. UAE: Darier Disease Market, by Treatment, 2019-2032 (USD Million)
      • 8.6.5.2. UAE.: Darier Disease Market, by End- User, 2019-2032 (USD Million)
      • 8.6.5.3. UAE: Darier Disease Market, by Application, 2019-2032 (USD Million)
    • 8.6.6. Darier Disease Market - Israel
      • 8.6.6.1. Israel: Darier Disease Market, by Treatment, 2019-2032 (USD Million)
      • 8.6.6.2. Israel.: Darier Disease Market, by End- User, 2019-2032 (USD Million)
      • 8.6.6.3. Israel: Darier Disease Market, by Application, 2019-2032 (USD Million)
    • 8.6.7. Darier Disease Market - South Africa
      • 8.6.7.1. South Africa: Darier Disease Market, by Treatment, 2019-2032 (USD Million)
      • 8.6.7.2. South Africa.: Darier Disease Market, by End- User, 2019-2032 (USD Million)
      • 8.6.7.3. South Africa: Darier Disease Market, by Application, 2019-2032 (USD Million)
  • 8.7. Darier Disease Market - Latin America
    • 8.7.1. Latin America: Darier Disease Market, by Treatment, 2019-2032 (USD Million)
    • 8.7.2. Latin America.: Darier Disease Market, by End- User, 2019-2032 (USD Million)
    • 8.7.3. Latin America: Darier Disease Market, by Application, 2019-2032 (USD Million)
    • 8.7.4. Darier Disease Market - Mexico
      • 8.7.4.1. Mexico: Darier Disease Market, by Treatment, 2019-2032 (USD Million)
      • 8.7.4.2. Mexico.: Darier Disease Market, by End- User, 2019-2032 (USD Million)
      • 8.7.4.3. Mexico: Darier Disease Market, by Application, 2019-2032 (USD Million)
    • 8.7.5. Darier Disease Market - Brazil
      • 8.7.5.1. Brazil: Darier Disease Market, by Treatment, 2019-2032 (USD Million)
      • 8.7.5.2. Brazil.: Darier Disease Market, by End- User, 2019-2032 (USD Million)
      • 8.7.5.3. Brazil: Darier Disease Market, by Application, 2019-2032 (USD Million)
    • 8.7.6. Darier Disease Market - Argentina
      • 8.7.6.1. Argentina: Darier Disease Market, by Treatment, 2019-2032 (USD Million)
      • 8.7.6.2. Argentina.: Darier Disease Market, by End- User, 2019-2032 (USD Million)
      • 8.7.6.3. Argentina: Darier Disease Market, by Application, 2019-2032 (USD Million)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. AbbVie
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Amneal Pharmaceuticals
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Bausch Health Companies
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. BridgeBio Pharma
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Galderma
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. GlaxoSmithKline
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Glenmark Pharmaceuticals
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Johnson and Johnson
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Laminar Pharma
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Mayne Pharma
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Merck
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Novartis
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Pfizer
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Benchmarking
    • 10.13.4. Recent Development
  • 10.14. Sawai Pharmaceutical
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Product Benchmarking
    • 10.14.4. Recent Development
  • 10.15. Sigmapharm Laboratories
    • 10.15.1. Company Overview
    • 10.15.2. Financial Performance
    • 10.15.3. Product Benchmarking
    • 10.15.4. Recent Development
  • 10.16. Sun Pharmaceutical
    • 10.16.1. Company Overview
    • 10.16.2. Financial Performance
    • 10.16.3. Product Benchmarking
    • 10.16.4. Recent Development
  • 10.17. Teva Pharmaceutical
    • 10.17.1. Company Overview
    • 10.17.2. Financial Performance
    • 10.17.3. Product Benchmarking
    • 10.17.4. Recent Development
  • 10.18. Tolmar Pharmaceuticals
    • 10.18.1. Company Overview
    • 10.18.2. Financial Performance
    • 10.18.3. Product Benchmarking
    • 10.18.4. Recent Development
  • 10.19. Validus Pharmaceuticals
    • 10.19.1. Company Overview
    • 10.19.2. Financial Performance
    • 10.19.3. Product Benchmarking
    • 10.19.4. Recent Development
  • 10.20. Viatris
    • 10.20.1. Company Overview
    • 10.20.2. Financial Performance
    • 10.20.3. Product Benchmarking
    • 10.20.4. Recent Development
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제